FDA Suspends Ban on Juul E-cigarette Sales

Jul.13.2022
FDA Suspends Ban on Juul E-cigarette Sales
The FDA temporarily suspends ban on Juul sales for extra review, but concerns over health risks persist.

The US Food and Drug Administration (FDA) has suspended its ban on the sale of Juul Labs' e-cigarettes, stating that additional scrutiny is required for the company's marketing application. Following Juul's appeal for an urgent review of the FDA's order, the federal appeals court decided to temporarily freeze the FDA's ban a few weeks ago.


However, this once flourishing company still remains in a difficult situation: the US Food and Drug Administration has only temporarily halted the re-evaluation ban, it has not been lifted.


Juul has been in the limelight in part due to its prominent position in the e-cigarette industry. However, as the company faces potential extinction, it may become the first casualty while the rest of the e-cigarette industry comes under increasing government scrutiny.


Dr. Zubair Karim, an assistant professor in the Department of Interdisciplinary Health Sciences at Augusta University, conducted research on Juul e-cigarettes and their potential to increase the risk of blood clots and other complications in users.


According to Karim, thrombosis is the partial or complete blockage of blood vessels, whether it occurs in veins or arteries, which restricts the natural flow of blood.


According to the location of blood clot formation, there are several potential complications. The most severe issues include stroke, heart attack, and a serious respiratory condition known as pulmonary embolism. Without prompt treatment, these conditions can be life-threatening. However, by focusing on lifestyle changes such as increasing physical activity, quitting smoking, losing weight, maintaining a balanced diet, avoiding junk food, and managing other health conditions, it is possible to prevent the disease from advancing.


As a ban on Juul products looms, it could lead to a ban on other companies' electronic cigarette products.


Karim stated, "This is the first step in banning e-cigarettes, and the FDA has taken an important and bold move.


Gradually, this will pave the way for the banning of other e-cigarette products. Juul and other products are no different, but Juul is becoming increasingly popular among our younger generation. Many localities and states have recently begun implementing laws banning the use of e-cigarettes, although some states with comprehensive smoke-free laws will still allow the use of e-cigarettes in bars and restaurants while prohibiting their use in other indoor venues.


For years, electronic cigarettes and their devices have been considered a "safer" alternative to traditional cigarettes, but their flavors and packaging have attracted children, and there are renewed efforts to study their possible side effects.


Looking at the long-term effects, both smoking and vaping have similar side effects and pose serious health risks. Scientists do not fully understand the long-term impact of vaping on health, but studies show that electronic cigarettes are not a safe alternative to smoking," said Karim.


In recent years, it has been observed that electronic cigarettes are becoming increasingly popular among young people. Additionally, electronic cigarettes contain high doses of nicotine, which is known to slow the development of fetuses, children, and adolescents' brains. Furthermore, electronic cigarettes involve inhaling aerosols that contain multiple chemicals, including those used for flavoring via electronic cigarettes or other devices. Additionally, the liquid produced in electronic cigarettes can be hazardous if swallowed, inhaled, or applied topically to the skin for both adults and children.


Despite this, e-cigarettes still contain harmful chemicals such as diacetyl, carcinogens, heavy metals, volatile organic compounds, and toxic chemicals not found in traditional cigarettes. In summary, the long-term toxic effects of e-cigarette use on overall health are similar to those of traditional cigarettes.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Spain Plans to Extend Smoking Ban to Terraces and Beaches, Bringing Vapes Under New Restrictions
Spain Plans to Extend Smoking Ban to Terraces and Beaches, Bringing Vapes Under New Restrictions
Spain is advancing a new tobacco-control reform that would expand smoking restrictions to additional public spaces, including restaurant terraces and beaches, while bringing vaping and other nicotine products into the same regulatory framework. The proposed measures aim to reduce secondhand smoke exposure, protect young people and expand smoke-free environments. The proposal remains under legislative development, and final implementation details have not yet been confirmed.
Jul.23
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
IQOS Global Flagship Space to Open in Tokyo Ginza as PMI Expands Consumer Experience Strategy
Philip Morris Japan (PMJ) announced that it will open “IQOS Flagship Ginza” in Tokyo on September 4, 2026. The location will become the first global flagship space for PMI’s IQOS brand. PMJ said the venue will target adult smokers aged 20 and above and combine product experiences, community engagement and local cultural elements. The design will incorporate Japanese natural aesthetics and traditional craftsmanship. The launch reflects PMI’s broader strategy of strengthening consumer engagement through experiential retail and brand spaces. The existing IQOS Store Ginza is scheduled to close on August 30, 2026.
Jul.21
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
BAT Regional Director Fred Monteiro Supports Spain’s Nicotine Rules but Opposes 0.99mg Nicotine Pouch Limit
Spanish newspaper El Confidencial interviewed Fred Monteiro, Regional Director for Americas and Europe at British American Tobacco (BAT). Monteiro said BAT supports setting regulatory limits for nicotine products but opposes Spain’s proposed 0.99mg nicotine-per-pouch limit, arguing that such a restriction could affect adult smokers’ transition to alternatives. He said nicotine regulation should be based on scientific evidence and harm reduction principles. Monteiro also said smoke-free products now account for around 25% of BAT’s Americas and Europe business and nearly 30% of its Europe business
BAT
Jul.30
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
China Discloses First Criminal Case Over Counterfeit Vapes Disguised as “Medical Nebulizers” and “Zero-Nicotine” Products
Chinese authorities have disclosed the country’s first reported criminal case involving counterfeit vapes marketed as “medical nebulizers” and “zero-nicotine” products. Authorities determined that the products involved were counterfeit vapes and pursued criminal charges for producing and selling counterfeit goods. According to the report, the case resulted in the seizure of 347,000 counterfeit vape pods and 53,700 vape devices, with physical goods valued at 22.13 million yuan.
Aug.04
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
Retail Case Study | Wisconsin Vape Market One Year After New Regulations: Johnny Vapes Reports 80% Sales Decline as Consumers Shift Online and Across State Lines
According to WNCY on August 24, 2026, some independent vape retailers in Wisconsin say they have faced significant business pressure one year after new vape regulations took effect. Johnny Vapes, a retailer operating in northeast Wisconsin, said its store count fell from seven locations to four, sales declined by about 80%, and roughly 90% of its inventory was affected. Retailers said some consumers have shifted to online purchases or traveled to neighboring Michigan to buy vape products. The case highlights how local regulations can reshape retail operations, inventory management and consumer purchasing patterns.
Aug.28